Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in<i>BRAF<sup>V600E</sup></i>-Mutated Anaplastic Thyroid Carcinoma

  • Jennifer R. Wang
    Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mark E. Zafereo
    Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ramona Dadu
    Division of Internal Medicine, Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Renata Ferrarotto
    Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Naifa L. Busaidy
    Division of Internal Medicine, Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Charles Lu
    Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Salmaan Ahmed
    Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Maria K. Gule-Monroe
    Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Michelle D. Williams
    Department of Pathology, and The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Erich M. Sturgis
    Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ryan P. Goepfert
    Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Neil D. Gross
    Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Stephen Y. Lai
    Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gary Brandon Gunn
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jack Phan
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • David I. Rosenthal
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Clifton David Fuller
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • William H. Morrison
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Priyanka Iyer
    Division of Internal Medicine, Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Maria E. Cabanillas
    Division of Internal Medicine, Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.

収録刊行物

  • Thyroid

    Thyroid 29 (8), 1036-1043, 2019-08-01

    Mary Ann Liebert Inc

被引用文献 (6)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ